Citadel Advisors
SPRB

Citadel Advisors’s Spruce Biosciences SPRB Stock Holding History

Citadel Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29
Closed -$1.04K – 15611
2024
Q3 		$1.04K Sell
29
-162
-85% -$5.93K ﹤0.01% 13914
2024
Q2 		$7.4K Buy
191
+59
+45% +$3.16K ﹤0.01% 13255
2024
Q1 		$7.78K Buy
+132
New +$33.6K ﹤0.01% 13596

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Citadel Advisors's SPRB Position: Q2 2026 in Review

Citadel Advisors reduced its Spruce Biosciences (SPRB) stake by 26% in Q2 2026, selling an estimated $1.01M and leaving 51,905 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #5815.

Citadel Advisors first reported a position in SPRB in Q4 2020 and has held it in 19 quarters since. The position peaked at $41.4M in Q4 2020. 64 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Citadel Advisors held 51,905 shares of Spruce Biosciences worth $2.8M as of Q2 2026.
  • Citadel Advisors sold 18,094 Spruce Biosciences shares in Q2 2026, an estimated $1.01M.
  • Spruce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5815 holding.
  • Citadel Advisors first reported a position in Spruce Biosciences in Q4 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Spruce Biosciences position peaked at $41.4M in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.